Literature DB >> 8039810

Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties.

C Schiller1, A Spittler, M Willheim, Z Szépfalusi, H Agis, M Köller, M Peterlik, G Boltz-Nitulescu.   

Abstract

Suramin, a polyanionic and polycyclic compound, was initially used for the treatment of trypanosomiasis and onchocerciasis. In the last decade, it has been used in therapy of cancer and acquired immune deficiency syndrome (AIDS). The influence of suramin on the expression of various markers by human mononuclear phagocytes is not known and was, therefore, presently investigated. Suramin inhibited the proliferation of U937 cells and mitogen-induced T-cell proliferation in a dose-dependent manner. The constitutive and cytokine-driven expression of Fc receptors for IgG (Fc gamma RI and Fc gamma RII), IgE (Fc epsilon RII) and IgA (Fc alpha R) on blood monocytes and U937 cells was suppressed by suramin. The basal level, as well as cytokine-induced major histocompatibility complex (MHC) class II antigens, was markedly diminished on suramin-treated monocytes. Furthermore, suramin dramatically reduced expression of CD14 and partially reduced complement receptor type 3 (CR3) and CR4 expression on monocytes. In contrast, suramin slightly induced MHC class I antigens on monocytes and CD71 on U937 cells. The capacity of monocytes to phagocytose IgG-sensitized ox erythrocytes, opsonized Escherichia coli, or fluorescein isothiocyanate (FITC)-conjugated latex beads was significantly inhibited. Northern blot analysis showed that the amount of Fc epsilon RII-specific mRNA was only partially reduced, suggesting that other mechanisms may be involved in the regulation of Fc epsilon RII expression. Our data demonstrate that suramin suppresses the expression of various cell-surface structures on human mononuclear phagocytes and impairs their phagocytic capacity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039810      PMCID: PMC1422361     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results.

Authors:  A M Levine; P S Gill; J Cohen; J G Hawkins; S C Formenti; S Aguilar; P R Meyer; M Krailo; J Parker; S Rasheed
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

Review 2.  Suramin: with special reference to onchocerciasis.

Authors:  F Hawking
Journal:  Adv Pharmacol Chemother       Date:  1978

3.  Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

Authors:  H Mitsuya; M Popovic; R Yarchoan; S Matsushita; R C Gallo; S Broder
Journal:  Science       Date:  1984-10-12       Impact factor: 47.728

4.  Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.

Authors:  J M Collins; R W Klecker; R Yarchoan; H C Lane; A S Fauci; R R Redfield; S Broder; C E Myers
Journal:  J Clin Pharmacol       Date:  1986-01       Impact factor: 3.126

5.  Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin.

Authors:  C Betsholtz; A Johnsson; C H Heldin; B Westermark
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

6.  Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells.

Authors:  M Pollak; M Richard
Journal:  J Natl Cancer Inst       Date:  1990-08-15       Impact factor: 13.506

7.  Molecular structure of human lymphocyte receptor for immunoglobulin E.

Authors:  H Kikutani; S Inui; R Sato; E L Barsumian; H Owaki; K Yamasaki; T Kaisho; N Uchibayashi; R R Hardy; T Hirano
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

8.  Suramin binds to platelet-derived growth factor and inhibits its biological activity.

Authors:  M Hosang
Journal:  J Cell Biochem       Date:  1985       Impact factor: 4.429

9.  Specificity of fc receptors for IgG2a, IgG1/IgG2b, and IgE on rat macrophages.

Authors:  G Boltz-Nitulescu; H Bazin; H L Spiegelberg
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

10.  Intralysosomal accumulation of polyanions. I. Fusion of pinocytic and phagocytic vacuoles with secondary lysosomes.

Authors:  M C Kielian; R M Steinman; Z A Cohn
Journal:  J Cell Biol       Date:  1982-06       Impact factor: 10.539

View more
  2 in total

1.  An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.

Authors:  Tracy R Daniels; Elizabeth Ortiz-Sánchez; Rosendo Luria-Pérez; Rafaela Quintero; Gustavo Helguera; Benjamin Bonavida; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  J Immunother       Date:  2011 Jul-Aug       Impact factor: 4.456

2.  IL-10 augments CD23 expression on U937 cells and down-regulates IL-4-driven CD23 expression on cultured human blood monocytes: effects of IL-10 and other cytokines on cell phenotype and phagocytosis.

Authors:  A Spittler; C Schiller; M Willheim; C Tempfer; S Winkler; G Boltz-Nitulescu
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.